Hiromichi Yuki

PDK1 inhibition is a novel therapeutic target in multiple myeloma

Saori Fujiwara, Yawara Kawano, Hiromichi Yuki et al. · British Journal of Cancer · 2012 · 139 citations · Full text

Medicine, Oncology, Pharmacology +17

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide

Yawara Kawano, Shiho Fujiwara, Naoko Wada et al. · International Journal of Oncology · 2012 · 115 citations · Full text

Medicine, Cell Biology, Hematology +16

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells

Hiromichi Yuki, Shikiko Ueno, Hiro Tatetsu et al. · Blood · 2012 · 47 citations · Full text

Medicine, Cancer Biology, Oncology +13

Rituximab Monotherapy and Rituximab-Containing Chemotherapy Were Effective for Paraneoplastic Pemphigus Accompanying Follicular Lymphoma, but not for Subsequent Bronchiolitis Obliterans

Taichi Hirano, Yusuke Higuchi, Hiromichi Yuki et al. · Journal of Clinical and Experimental Hematopathology · 2015 · 18 citations · Full text

Medicine, Immunology, Pharmacotherapy +15

Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells

Shinya Endo, Masayuki Amano, Nao Nishimura et al. · Biochemical and Biophysical Research Communications · 2015 · 13 citations

Medicine, Molecular Biology, Oncology +17